Sylvamo (SLVM) Q3 2026 Earnings Call Transcript

Sylvamo reported third-quarter continuing-operations sales of $645 million and adjusted EBITDA of $128 million, up from $66 million in the prior quarter, with a 20% EBITDA margin; adjusted operating earnings were $1.33 per diluted share. The company entered a put-option agreement for a proposed sale of its European business, retaining an indefinite 20% economic interest in future distributions and sale proceeds, with closing expected by the end of Q1 2027 subject to consultation and approvals. Eastover's 60,000-short-ton annual capacity project is about 60% complete, while Sumter's planned expansion adds 200,000 short tons of annual converting capacity and requires an additional $25 million of 2027 capital expenditure; management cited more than a 30% expected IRR for the combined investments. Input and transportation costs were $6 million unfavorable in Q3, with a similar sequential headwind expected in Q4.

Analysis

The quarter’s EBITDA rebound overstates the improvement in the underlying run rate: the absence of scheduled outages contributed $38 million sequentially, while price/mix added $25 million; meanwhile, management expects another roughly $6 million of sequential input and freight pressure in Q4 and describes 2027 costs as about $50 million above 2025. The key test is whether pricing, lean savings and internal converting offset this structurally higher cost base—not whether one outage-free quarter annualizes.

The Europe exit could simplify the equity story, but it is not yet a clean value-unlock catalyst. The disclosed terms provide no sale price, and the retained 20% is an indefinite, non-controlling claim on future distributions and proceeds. That makes valuation dependent on buyer execution and cash actually distributed; confirm the signed purchase agreement, closing conditions, liability allocation and any stranded costs before crediting proceeds or a multiple uplift. The continuing business also inherits about $6.5 million quarterly corporate costs previously allocated to Europe; future reductions are possible, not committed.

Near term, monitor Q4 working-capital unwind and freight/input costs. Over 1–3 months, the Europe consultation and definitive agreement are the principal catalysts. In 6–18 months, Eastover ramp and Sumter’s later start-up may improve economics, but execution and customer demand matter. Riverdale’s supply removal supports industry pricing, yet rising imports are a counterweight; the announced Canadian tariff scope is not, by itself, a strong earnings catalyst. Contrarian point: focus shift and projected project returns may attract rerating, but the market could be capitalizing prospective benefits before sale consideration, normalized FCF and post-divestiture overhead are evidenced.

Key Decisions for Investors

• Do not underwrite a Europe-sale-driven re-rating yet. Track signing/closing milestones and verify consideration, cash/debt and working-capital treatment, transferred liabilities, and residual obligations in the definitive documents.
• For SLVM, prefer a watchlist/conditional entry over chasing the earnings headline: consider adding only after Q4 results show the expected working-capital release and pricing/productivity are absorbing freight and input inflation. Thesis weakens if cash conversion disappoints or price realization reverses.
• Track Eastover’s early-2027 ramp and Sumter’s planned mid-2027 start-up against volumes, outsourced converting expense and incremental capital spending. If milestones slip or savings fail to appear, reduce expected earnings uplift; no clean IP pair trade is established by these facts alone.